i-base Pocket size Pocket size Hepatitis C for people with HIV

Similar documents
THIS IS AN OFFICIAL NH DHHS HEALTH ALERT

The High way code. the guide to safer, more enjoyable drug use. (alcohol)

Were the babies switched? The Genetics of Blood Types i

CHAPTER HEPATITIS C (3 CONTACT HOURS) Learning objectives Introduction History Prevalence

The High way code. the guide to safer, more enjoyable drug use [GHB] Who developed it?

The High way code. the guide to safer, more enjoyable drug use. (stimulants)

The High way code. the guide to safer, more enjoyable drug use. (ketamine)

Joint Modelling Approaches in diabetes research. Francisco Gude Clinical Epidemiology Unit, Hospital Clínico Universitario de Santiago

The High way code. the guide to safer, more enjoyable drug use. [cannabis] Who developed it?

AlereTM. i Influenza A & B. Enter. Molecular results in less than 15 minutes

A national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia

Gurprit Grover and Dulumoni Das* Department of Statistics, Faculty of Mathematical Sciences, University of Delhi, Delhi, India.

The High way code. the guide to safer, more enjoyable drug use. (lsd / magic mushrooms)

The High way code. the guide to safer, more enjoyable drug use [MDMA] Who developed it?

The High way code. the guide to safer, more enjoyable drug use. (mdma)

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

Supplement. PART A: Methods. In order to estimate population-wide HIV transmission and progression rates, we

REF. Instruction Manual. Scaler tips. 1 Symbols. 2 Safety. See Section 2 Safety. Important information for users

THE NORMAL DISTRIBUTION AND Z-SCORES COMMON CORE ALGEBRA II

Copy Number Variation Methods and Data

Price linkages in value chains: methodology

Pocket size ART. i-base

CT scans (Computed Tomography) Information for patients Radiology

Modeling the Survival of Retrospective Clinical Data from Prostate Cancer Patients in Komfo Anokye Teaching Hospital, Ghana

Optimizing an HIV testing program using a system dynamics model of the continuum of care

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

SECTION 6. HCV DIAGNOSTICS FOR MAKING TREATMENT DECISIONS

Using the Perpendicular Distance to the Nearest Fracture as a Proxy for Conventional Fracture Spacing Measures

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

Statistical Analysis on Infectious Diseases in Dubai, UAE

A GEOGRAPHICAL AND STATISTICAL ANALYSIS OF LEUKEMIA DEATHS RELATING TO NUCLEAR POWER PLANTS. Whitney Thompson, Sarah McGinnis, Darius McDaniel,

Ependymal cells Cilia on one surface Movement of material or fluid over surface of the cell

Strategies for the Early Diagnosis of Acute Myocardial Infarction Using Biochemical Markers

CONSTRUCTION OF STOCHASTIC MODEL FOR TIME TO DENGUE VIRUS TRANSMISSION WITH EXPONENTIAL DISTRIBUTION

THE NATURAL HISTORY AND THE EFFECT OF PIVMECILLINAM IN LOWER URINARY TRACT INFECTION.

HEPATITIS C TREATMENT GUIDANCE

Understanding the Aging Chromosome Dance cont.

Project title: Mathematical Models of Fish Populations in Marine Reserves

The Interaction Effects of the Factors Influencing Knowledge and. Consciousness of the Infectious Diseases: Bangladeshi Population

Effect of Strongyloides stercoralis Infection and Eosinophilia on Age at Onset and Prognosis of Adult T-Cell Leukemia

PANCREATIC CANCER. - Exocrine: the production of enzymes that help digesting fats and proteins.

EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE

Hepatitis C Medications Prior Authorization Criteria

Association Analysis and Distribution of Chronic Gastritis Syndromes Based on Associated Density

Fitsum Zewdu, Junior Research Fellow. Working Paper No 3/ 2010

CT abdomen. with prolonged oral preparation. Information for patients Radiology

TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II)

Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus

HIV/AIDS-related Expectations and Risky Sexual Behavior in Malawi

Study and Comparison of Various Techniques of Image Edge Detection

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

29th Viral Hepatitis Prevention Board Meeting

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

The Importance of Being Marginal: Gender Differences in Generosity 1

Lateral Transfer Data Report. Principal Investigator: Andrea Baptiste, MA, OT, CIE Co-Investigator: Kay Steadman, MA, OTR, CHSP. Executive Summary:

Case 1:09-cv RWS Document 162 Filed 12/23/2009 Page 1 of 5. , UNITED STATES DISTRICT COURT 'i FOR THE SOUTHERN DISTRICT OF NEW YORK.

A Clinician-mediated, Longitudinal Tracking System for the Follow-up of Clinical Results

Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside

Discussion Papers In Economics And Business

HIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER LONDON

Disablement and Quality of Life After Stroke

General Statement for Drugs for the Treatment of Hepatitis C

Selecting HCV Treatment

Delving Beneath the Covers: Examining Children s Literature

HIV/AIDS-related Expectations and Risky Sexual Behavior in Malawi

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

~-240 logical Societies /94/$ chain reaction

RODWELL HOUSE WOUND ASSESSMENT

Systematic review and meta-analysis Tropical Medicine Nov, 4 th 2016

Allergy services. Still not meeting the unmet need. Report of the Joint Royal College of Physicians and Royal College of Pathologists Working Party

LETTERS. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection

Estimating the distribution of the window period for recent HIV infections: A comparison of statistical methods

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

National Clinical Guidelines for the treatment of HCV in adults. Version 5

Drug Class Prior Authorization Criteria Hepatitis C

ACCU-CHEK. Compact Plus. User s Manual BLOOD GLUCOSE MONITORING SYSTEM. Downloaded from manuals search engine

National Clinical Guidelines for the treatment of HCV in adults. Version 4

USING DIFFERENTIAL GEOMETRIC LARS ALGORITHM TO STUDY THE EXPRESSION PROFILE OF A SAMPLE OF PATIENTS WITH LATEX-FRUIT SYNDROME

National Clinical Guidelines for the treatment of HCV in adults. Version 3

Using Past Queries for Resource Selection in Distributed Information Retrieval

HPI (2006) Question: Douglas T. Dieterich, MD. What is the risk of mother-to-child transmission in HCV for this woman?

A MIXTURE OF EXPERTS FOR CATARACT DIAGNOSIS IN HOSPITAL SCREENING DATA

Title. Author(s)Salmingo, Remel; Tadano, Shigeru; Fujisaki, Kazuhiro. CitationClinical Biomechanics, 27(6): Issue Date Doc URL.

Carcinoembryonic antigen in patients with intraeranial tumors

Decreased Nailfold Capillary Density in Limited Scleroderma with Pulmonary Hypertension. and a longer disease duration. 3,4

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

310 Int'l Conf. Par. and Dist. Proc. Tech. and Appl. PDPTA'16

SMALL AREA CLUSTERING OF CASES OF PNEUMOCOCCAL BACTEREMIA.

Pharmacological management of viruses in obese patients

Encoding processes, in memory scanning tasks

Unproven treatments and motor neurone disease

International Journal of Emerging Technologies in Computational and Applied Sciences (IJETCAS)

Treatment guidance for Chronic Hepatitis C Infection

SW LRT Station Areas Quick Facts

Richard Williams Notre Dame Sociology Meetings of the European Survey Research Association Ljubljana,

Validation of the Gravity Model in Predicting the Global Spread of Influenza

Lymphoma Cancer Classification Using Genetic Programming with SNR Features

Horizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688

Clinical Genetics Welcome to Clinical Genetics

Transcription:

Pocket sze Pocket sze -base Hepatts C for people wth HIV March 2017

Ths leaflet s about confecton wth both hepatts C (HCV) and HIV. Web lnks are for more nformaton.

HIV s now easy to treat and HCV can be cured (wth DAAs). The meds work very well wth low rsk of sde effects. HIV meds are now wdely avalable n every country. Gettng DAAs s more dffcult, even n the UK. DAA = drect actng antvral. -base.nfo/daas

Fndng a doctor Fndng out you have HCV can be dffcult, especally f you have been HIV postve for many years. Or perhaps you may have known about HCV for a long tme and are only now thnkng about treatment. Whatever your stuaton, many people have both nfectons. HCV s usually a slow nfecton. -base.nfo/hepc

DAAs cure HCV n more than 95% of people - from 1 or 2 plls a day, usually for only 12 weeks. You wll need a doctor that understands confecton. If you have dfferent doctors for HIV and HCV, they need to work wth each other.

Dagnosng HCV Two tests are needed: 1. An HCV antbody test. A postve antbody result means that you ether have HCV now or that you had t before and cleared t. A negatve result mght also mean that you caught HCV recently. Ths test wll not detect early HCV because t can take 6-24 weeks after nfecton for HCV antbodes to develop. Also, f your CD4 count s less than 200, you may not make antbodes to HCV.

2. An HCV vral load (RNA) test wll confrm or rule out actve nfecton. HCV vral load tests look for the vrus n the same way as HIV vral load tests. If you have detectable HCV vral load, t means that you have current HCV nfecton. If your HCV vral load s undetectable, a second test should be done sx months later. Two undetectable vral load results show that your mmune system has cleared HCV. -base.nfo/gudes/hepc/testng

Other tests for your HCV care These other tests are mportant for montng your health HCV vral load (RNA) HCV genotype (mportant for treatment optons). Hep B and hep A. Complete blood count (CBC) and blood clottng tme. Lver enzyme tests (ALT AST, albumn and GGT) Fbroscan or alternatve non-nvasve test.

Checkng your lver In the UK, non-nvasve tests lke a FbroScan are used to measure lver damage. Ths has replaced the need for lver bopsy n most cases. www.youtube.com/ watch?v=l_e4zgmkooa In ths YouTube vdeo, Dr Sanjay Baghan from the Royal Free Hosptal n London shows how a Fbroscan works.

New HCV drugs Snce 2014, many drect actng antvrals (DAAs) have been approved and others are n development. DAAs have very hgh cure rates from short-course oral treatment and few sde effects. The drugs are not expensve to make, but the prce charged to the NHS s very hgh. Current DDAs nclude: sofosbuvr, ledpasvr, smeprevr, daclatasvr, ombtasvr, partaprevr/r, dasabuvr, elbasvr, grazoprevr and velapatasvr. -base.nfo/daas

All hepc gudelnes now recommend DAAs, sometmes wth rbavrn, but they need to be chosen carefully. Older HCV drugs For many years HCV was treated wth pegylated nterferon (PEG-IFN) plus rbavrn (RBV). These drugs are less effectve, especally aganst some HCV genotypes. They nvolve longer treatment wth more dffcult sde effects. In the UK, some people wll stll be offered PEG-IFN and RBV.

Gettng new HCV meds n the UK DAAs are avalable free on the NHS, but they may not always be avalable to everyone who has HCV. Only people wth the most advanced lver dsease are gettng prorty to DAAs. Retreatment s not avalable, for example, f you become renfected. Some people are buyng generc DAAs onlne (at much lower prces) to get better and faster treatment.

Buyng new HCV meds onlne Anyone n the UK can buy medcnes for personal use from an onlne pharmacy. Onlne generc DAAs cost about 1200 (vs. more than 30,000 pad by the NHS). In some countres generc DAAs cost less than 500. Your HIV doctor should be able to advse you on whch meds would work for you and on extra montorng tests. -base.nfo/qa/10734 fxhepc.com

Access to DAAs Gettng access to DAAs for everyone needs the NHS to negotate much cheaper prces and the drug companes to aggree to ths. Although HCV progresses slowly n many people, everyone should have the chance to be cured. Get nvolved n mprovng access. Wrte to your MP and Hosptal Trust. Jon a communty campagn. Generc versons of these meds only cost less than $500 to manufacture.

More nfo Ths leaflet s shortened from a much longer booklet on confecton. -base.nfo/gudes/hepc The full booklet ncludes more nformaton about transmsson, dagnoss, treatment and support about lvng wth HCV confecton. Informaton s all onlne or we can post you a free prnt copy. -base.nfo/order -Base, 107 The Maltngs, London, SE1 3LJ.

More pages >>> New HCV meds can cure nearly everyone... They should be avalable to everyone wth HCV.